References
- Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol 1997; 10(3)136–145
- Ciancio G, Siquijor A P, Burke G W, Roth D, Cirocco R, Esquenazi V, et al. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. Clin Transplant 1997; 11(3)243–249
- Martinenghi S, Dell'Antonio G, Secchi A, Di C, Pozza V. G. Cancer arising after pancreas and/or kidney transplantation in a series of 99 diabetic patients. Diabetes Care 1997; 20(3)272–275
- Mosier D E. Epstein–Barr virus and lymphoproliferative disease. Curr Opin Hematol 1999; 6(1)25–29
- Cleary M, Warnke L. K., Sklar J. Monoclonality of lymphoproliferative lesions in cardiac-transplant recipients. Clonal analysis based on immunoglobulin- gene rearrangements. N Engl J Med 1984; 310(8)477–382
- Cesarman E, Chadbum A, Liu Y F, Migliazza A, Dalla-Favera R, Knowles D M. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 1998; 92(7)2294–2302
- Knowles D M, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose E A, et al. Correlative morphologie and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85(2)552–565
- Chadburn A, Chen J M, Hsu D T, Frizzera G, Cesarman E, Garrett T J, et al. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Cancer 1998; 82(10)1978–1987
- Swinnen L J., Mullen G M, Carr T J, Costanzo M R, Fisher R I. Aggressive treatment fo2 r posteardiac transplant lymphoproliferation. Blood 1995; 86(9)3333–3340
- Davis C L, Wood B L, Sabath D E, Joseph J S, Stehman-Breen C, Broudy V C. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998; 66(12)1770–1779
- De Mario M D, Liebowitz D N. Lymphomas in the immunocompromised patient. Semin Oncol 1998; 25(4)492–502
- Nalesik M A, Rao A S, Furukawa H, Pham S, Zeevi A, Fung J J, et al. Autologous lymphokine-activated killer cell therapy of Epstein-Ban virus-positive and-negative lymphoproliferative disorder arising in organ transplant recipients. Transplantation 1997; 63(9)1200–1205
- Benkerron M, Jais J P, Leblond V, Durandy A, Sutton L, Bordigoni P, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998; 92(9)3137–3147
- Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92(6)1927–1932